BASF's Evonik Overture Rattles Shareholders as Ag Spinoff Clock Ticks

BASF closed at EUR 50.89 after confirming exploratory Evonik takeover talks, while Evonik says no talks are currently taking place.

BASF shares shed 2.6% on Friday to close at EUR 50.89, as the chemicals group's confirmation that it is weighing a takeover of Essen-based specialty chemicals rival Evonik Industries gave investors pause. At one point during the session the stock was down more than 3%, according to media reports, while Evonik's own shares moved noticeably higher.

The Ludwigshafen group said it was holding exploratory talks with both the RAG-Stiftung foundation and Evonik itself about a possible acquisition of its competitor, stressing that neither the progress nor the outcome of those discussions could be predicted. Evonik, for its part, acknowledged an unsolicited approach regarding a voluntary public takeover offer for all of its shares — but added that no talks are currently taking place. That contradiction between the two companies' statements only deepened the confusion among market participants about how far the two sides have actually moved toward each other.

A Sensitive Moment for the Group's Overhaul

The timing is awkward. BASF is in the middle of a sweeping restructuring and a strategic realignment of its divisions, and a multibillion-euro domestic acquisition would pile integration and financing tasks onto an already crowded agenda. Investors are now weighing whether such a move would strengthen the transformation or complicate existing reform efforts — and, above all, whether management can maintain financial discipline or is overreaching with a major project. Clarity on how much capital a deal would tie up is what the market wants.

The group is already juggling several capital-intensive initiatives. It is examining an MDI investment in India, for which a subsidiary has already secured an industrial plot in Dahej. At the same time, BASF is separating peripheral businesses to free up liquidity.

Four Banks, One IPO, and a 3% Slide

Roughly two weeks ago, the company mandated four major banks — Citi, Deutsche Bank, Goldman Sachs and J.P. Morgan — as global coordinators to prepare a listing of its Agricultural Solutions division, targeted for the first half of 2027. Since that announcement, the stock has lost 3.0%. The planned independence of the agricultural business is considered a cornerstone of the ongoing portfolio cleanup, and the balancing act between divestments on one side and fresh takeover ambitions on the other is what has unsettled market participants.

On the analyst front, there was some tailwind. Bernstein Research raised its price target for BASF from EUR 62 to EUR 63 after talks with management, keeping its "Outperform" rating and slightly lifting its third-quarter EBITDA forecast.

The Bull and Bear Cases

In an optimistic scenario, BASF succeeds in adding high-quality specialty chemicals activities to its portfolio without paying inflated prices. Consolidation in the German chemicals sector could unlock significant savings in research, sales and administration, while a stronger specialty products business would reduce dependence on cyclical base chemicals. Advocates of a disciplined strategic purchase argue it could durably reinforce BASF's market position in selected core segments. Should the exploratory talks fail or be abandoned early without financial cost, the focus would swing fully back to the existing cost-cutting program.

The bear case centers on the fear of an expensive transaction at the wrong time. If the unsolicited approach turns into a formal offer for all Evonik shares, a substantial premium would likely be due — a burden on the balance sheet that would curb room for future dividends or share buybacks. Add to that the integration risk: merging two German chemicals groups with complex Verbund sites and regulatory requirements would tie up management capacity for years. And because Evonik has said no talks are currently underway, the prospect of a protracted or even hostile takeover battle looms, which could seriously shake investor confidence in the group's strategic reliability.

What to Watch Next

Technically, the picture remains intact for now: at EUR 50.89, the stock still trades about 2.8% above its 200-day moving average of EUR 49.50. Should that support give way amid further takeover uncertainty, selling pressure could intensify in the short term. Concrete answers on the state of the Evonik talks — and on operations — will arrive in a few weeks, when BASF publishes its written information for the third quarter of 2026 on October 28 from 7:00 a.m. Until then, every comment from the executive board on its Evonik plans is likely to set the tone for the share price.